Table 4.
The multivariate analysis of risk factors for survivals
| PFS | OS | |||
|---|---|---|---|---|
|
|
|
|||
| HR (95 CI) | p-value | HR (95 CI) | p-value | |
| Histologic subtype | ||||
| SCC | Ref | 0.423 | 1.606 (0.928-2.777) | 0.090 |
| Adenocarcinoma | 0.809 (0.482-1.359) | Ref | ||
| Gender | ||||
| Woman | Ref | 0.201 | Ref | 0.609 |
| Man | 1.684 (0.758-3.742) | 1.266 (0.513-3.124) | ||
| Liver Metastasis | ||||
| No | Ref | 0.675 | 0.748 | |
| Yes | 1.122 (0.655-1.921) | 1.115 (0.575-2.161) | ||
| Bone Metastasis | ||||
| Yes | Ref | 0.046 | 1.810 (1.064-3.079) | 0.029 |
| No | 0.598 (0.361-0.992) | Ref | ||
| Opioid Using | ||||
| No | Ref | 0.267 | 0.798 (0.096-6.618) | 0.835 |
| Yes | 3.166 (0.413-24.254) | Ref | ||
| Tramadol | ||||
| No | Ref | 0.510 | Ref | 0.350 |
| Yes | 1.255 (0.639-2.467) | 1.402 (0.691-2.846) | ||
| Morphine | ||||
| No | 0.977 (0.289-3.306) | 0.970 | 0.925 (0.242-3.534) | 0.909 |
| Yes | Ref | Ref | ||
| Fentanyl | ||||
| No | 0.608 (0.333-1.111) | 0.106 | 0.675 (0.359-1.270) | 0.223 |
| Yes | Ref | Ref | ||
| Codein | ||||
| No | Ref | 0.474 | 0.694 | |
| Yes | 1.256 (0.673-2.343) | 1.148 (0.577-2.287) | ||
HR, hazard ratio; OS, Overall survival; PFS, progression-free survival; Ref, reference; SCC, squamous cell carcinoma.